Advanced Breast Cancer Biomarkers Identified in Study
Researchers have identified immune-related pathways that correlate with responses to specific immunotherapy combinations.
Updated on Sept. 19, 2026 in Cancer
Live Poll
Do you believe new drug combination research effectively improves long-term cancer patient outcomes?
A clinical study of 19 patients with advanced HER2-negative breast cancer identified specific immune pathways linked to treatment success. This research clarifies potential indicators for how patients may respond to therapy regimens involving entinostat, nivolumab, and ipilimumab.
Why it matters
Identifying these pathways may eventually help refine treatment strategies for advanced breast cancer. Understanding these response patterns is a step toward determining which patients are most likely to benefit from specific immunotherapy-based combinations.
In a Phase Ib trial of 19 patients, researchers analyzed 37 tumor biopsies using RNA-sequencing and T-cell receptor analysis. Responders exhibited baseline enrichment of inflammatory and interferon pathways, though these findings remain preliminary.
The players
NCT02453620
This is the clinical trial identifier for the study examining the safety and efficacy of the triplet therapy combination.
The details
Researchers utilized RNA-sequencing, T-cell receptor repertoire data, and neoantigen analysis to observe how tumor environments shift during treatment. By performing biopsies at multiple intervals, they identified that patients who responded to the triplet therapy showed higher T-cell receptor diversity. The study also used PAM50 analysis to categorize the specific tumor subtypes within the cohort.
Timeline
• Researchers collected post-triplet therapy biopsies at Week 8.
Health Landscape
This research contributes to the clinical evaluation of immunotherapy for HER2-negative breast cancer by characterizing how immune-related pathways influence patient response. It sits within a broader scientific effort to map how tumor microenvironments evolve during intensive triplet therapy.
These findings are early-stage and intended for the research community rather than immediate clinical application. Any questions regarding current treatment options or clinical trial eligibility should be discussed directly with your oncologist.
The takeaway
This study highlights the importance of baseline inflammatory and interferon pathways in predicting immune response. Patients or caregivers interested in how molecular markers influence care should consult with their specialist about current advancements in breast cancer research.
Further reading
Learn more about the latest research on Cancer.
More information
Review the complete peer-reviewed research article for full technical findings.
Live Poll
Do you believe new drug combination research effectively improves long-term cancer patient outcomes?
